| Cover | Jun. 21, 2022 |
| Cover [Abstract] | |
| Document Type | 8-K/A |
| Document Period End Date | Jun. 21, 2022 |
| Entity Registrant Name | Balchem Corp |
| Entity Incorporation, State or Country Code | MD |
| Entity File Number | 1-13648 |
| Entity Tax Identification Number | 13-2578432 |
| Entity Address, Address Line One | 52 Sunrise Park Road |
| Entity Address, City or Town | New Hampton |
| Entity Address, State or Province | NY |
| Entity Address, Postal Zip Code | 10958 |
| City Area Code | 845 |
| Local Phone Number | 326-5600 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Stock, par value $.06-2/3 per share |
| Trading Symbol | BCPC |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |
| Amendment Description | Explanatory NoteAs previously reported, on June 13, 2022, Balchem Corporation, (“Balchem”), and its wholly-owned subsidiary, Balchem B.V., a Dutch company (Balchem and Balchem B.V. being hereinafter collective referred to as “Buyers”), entered into a Share Purchase Agreement (the “Agreement”) among Buyers and Kechu MidCo AS, as seller (“Seller”), providing for the purchase by Buyers of Kechu BidCo AS and its subsidiary companies, including Kappa Bioscience AS, a leading science-based manufacturer of specialty Vitamin K2 for the human nutrition industry, headquartered in Oslo, Norway (hereinafter collectively referred to as “Kappa”).On June 21, 2022, Buyers closed their acquisition of Kappa (the “Closing”). Prior to the Closing, neither Buyers, nor any of their respective affiliates, nor any of their respective directors or officers, nor any associate of any of their respective directors or officers had any material relationship with any of the other parties to the Agreement, other than with respect to the acquisition.On June 27, 2022, Balchem filed a Current Report on Form 8-K (the “Current Report”) to report the closing of its acquisition of Kappa. The purpose of this Amendment No. 1 to the Current Report is to file the financial statements and the pro forma financial information required by Item 9.01 of Form 8-K. Accordingly, Balchem hereby amends Item 9.01 of the Current Report to read in its entirety as set forth below. |
| Amendment Flag | true |
| Entity Central Index Key | 0000009326 |
